大石 徹郎

• 2013 - 2015 卵巣明細胞腺癌におけるPI3K阻害薬の至適併用療法選択と感受性マーカー探索
• 2007 - 卵巣明細胞腺癌に対するERKを標的とした分子標的治療
• 2007 - ERK-targeted therapy in ovarian clear cell carcinoma
• 2002 - 2004 卵巣明細胞腺癌の細胞生物学的特性の解明と抗癌剤耐性克服の試み
• 2002 - -

• Komatsu H, Oishi T, Sato S, Osaku D, Sawada M, Kudoh A, Nonaka M, Sato S, Shimada M, Itamochi H, et al. Evaluating Chemotherapy-induced Nausea and Vomiting and Food Intake in Patients With Gynecologic Cancer. Anticancer Res. 2019. 39. 8. 4555-4560
• Sawada M, Oishi T, Komatsu H, Sato S, Chikumi J, Nonaka M, Kudoh A, Osaku D, Harada T. Serum vascular endothelial growth factor A and vascular endothelial growth factor receptor 2 as prognostic biomarkers for uterine cervical cancer. Int J Clin Oncol. 2019
• Komatsu H, Oishi T, Osaku D, Sawada M, Kudoh A, Nonaka M, Chikumi J, Sato S, Harada T. Significance of High-Risk Human Papillomavirus Testing for Atypical Glandular Cells on Cervical Cytology. Acta Cytol. 2018. 10. 5-6. 1-6
• Hiroaki Komatsu, Tetsuro Oishi, Hiroaki Itamochi, Muneaki Shimada, Shinya Sato, Jun Chikumi, Seiya Sato, Michiko Nonaka, Mayumi Sawada, Makoto Wakahara, et al. Serum Vascular Endothelial Growth Factor-A as a Prognostic Biomarker for Epithelial Ovarian Cancer. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. 2017. 27. 7. 1325-1332
• Itamochi H, Oishi T, Oumi N, Takeuchi S, Yoshihara K, Mikami M, Yaegashi N, Terao Y, Takehara K, Ushijima K, et al. Whole-genome sequencing revealed novel prognostic biomarkers and promising targets for therapy of ovarian clear cell carcinoma. Br J Cancer. 2017. 117. 5. 717-724

もっと見る

• Seiya Sato, Hiroaki Itamochi, Junzo Kigawa, Tetsuro Oishi, Muneaki Shimada, Shinya Sato, Jun Naniwa, Kazunori Uegaki, Michiko Nonaka, Naoki Terakawa. Combination chemotherapy of oxaliplatin and 5-fluorouracil may be an effective regimen for mucinous adenocarcinoma of the ovary: A potential treatment strategy. CANCER SCIENCE. 2009. 100. 3. 546-551
• R. Shimogai, J. Kigawa, H. Itamochi, T. Iba, Y. Kanamori, T. Oishi, M. Shimada, S. Sato, W. Kawaguchi, S. Sato, et al. Expression of hypoxia-inducible factor 1 alpha gene affects the outcome in patients with ovarian cancer. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. 2008. 18. 3. 499-505
• R. Shimogai, J. Kigawa, H. Itamochi, T. Iba, Y. Kanamori, T. Oishi, M. Shimada, S. Sato, W. Kawaguchi, S. Sato, et al. Expression of hypoxia-inducible factor 1 alpha gene affects the outcome in patients with ovarian cancer. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. 2008. 18. 3. 499-505
• Wakae Kawaguchi, Hiroaki Itamochi, Junzo Kigawa, Yasunobu Kanamori, Tetsuro Oishi, Muneaki Shimada, Sinya Sato, Ruri Shimogai, Seiya Sato, Naoki Terakawa. Simultaneous inhibition of the mitogen-activated protein kinase kinase and phosphatidylinositol 3'-kinase pathways enhances sensitivity to paclitaxel in ovarian carcinoma. CANCER SCIENCE. 2007. 98. 12. 2002-2008
• T. Oishi, H. Itamochi, J. Kigawa, Y. Kanamori, M. Shimada, M. Takahashi, R. Shimogai, W. Kawaguchi, S. Sato, N. Terakawa. Galectin-3 may contribute to Cisplatin resistance in clear cell carcinoma of the ovary. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. 2007. 17. 5. 1040-1046

もっと見る

• よくわかる卵巣癌のすべて/安田允・編著(分担執筆)
  永井書店 2007

• - 1999 鳥取大学 医学研究科 外科系専攻
• - 1999 鳥取大学
• - 1994 鳥取大学 医学部 医学科
• - 1994 鳥取大学

• 博士(医学) (鳥取大学)

• 2010/04 - 鳥取大学医学部附属病院 講師
• 2010 - - Lecturer,
• 2007/04 - 鳥取大学医学部 助教
• 2007 - - Assistant professor, Faculty of Medicine,
• 2002/01 - 鳥取大学医学部 助手
2002 - - 6 Research Associate, Faculty of Medicine,
Tottori University Hospital
鳥取大学

• 2018/07 - 現在 日本婦人科腫瘍学会 理事
• 2016 - 現在 日本婦人科腫瘍学会 代議員
• 2009 - 現在 日本臨床細胞学会 評議員

American Association for Cancer Research ,  日本臨床細胞学会 ,  婦人科悪性腫瘍化学療法研究機構 ,  日本婦人科腫瘍学会 ,  日本癌治療学会 ,  日本癌学会 ,  日本産科婦人科学会 ,  JSCC ,  AACR ,  JGOG ,  JSGO ,  JSCO ,  JCA ,  JSOG ,  日本人類遺伝学会 ,  日本婦人科がん検診学会